Tevogen Bio Holdings Inc.

Tevogen Bio Holdings Inc. (Nasdaq: LGST) is a clinical-stage biopharmaceutical company that entered the public markets through a SPAC merger, operating in the healthcare and life sciences sector with a focus on off-the-shelf T-cell immunotherapy candidates targeting viral diseases and oncological indications. The company filed a Form 10-Q with the Securities and Exchange Commission on May 22, 2023, reflecting its status as a recently public entity in the early stages of clinical development. The quarterly disclosure covers financial results and operational updates as Tevogen Bio advances its proprietary immunotherapy platform. For full filing history, sponsor details, and deep-dive analytics on LGST and the broader SPAC universe, sign up for complete data access at SpacDesk.